Related Experiment Video
Updated: Sep 17, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Mucin-1: a promising pan-cancer therapeutic target
Udhayvir Singh Grewal1, Razelle Kurzrock2
1Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. udhayvir-grewal@uiowa.edu.
Abstract:
Mucin1 or MUC1 (also known as CD227, EMA, MCD, MAM6, PEM, PUM, KL-6, CA 27.29/CA 15-3) is a highly glycosylated transmembrane mucin family member protein that is overexpressed in various solid or hematological cancers. Abnormal MUC1 expression/glycosylation in cancer leads to the activation of multiple pathways, resulting in tumor migration, invasion and accelerated growth. CA 27.29/CA 15-3 are blood tumor markers used in breast cancer patients. Novel therapeutic agents targeting MUC1, including cancer vaccines, cellular therapies, radiopharmaceuticals, monoclonal antibodies and antibody-drug conjugates, are being explored in clinical studies. The current review summarizes the molecular mechanisms of MUC1 in cancer and highlights existing data for MUC1-targeting agents in the therapeutic pipeline.
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

